Markets:

Overview

News

Currencies

International

Treasuries

Longeveron Inc. - Class A Common stock (NQ:LGVN)

0.8149 -0.0251 (-2.99%)

Streaming Delayed Price Updated: 12:49 PM EDT, Aug 24, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Longeveron Inc. - Class A Common stock

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

16 17 Next >

Elon Musk Is a Genius Market Timer. That’s Bad News for Tesla (TSLA) Stock. ↗

December 19, 2022

Elon Musk is great at timing the market. He's selling TSLA stock now, and savvy investors would be wise to follow suit.

Via InvestorPlace

Why Quotient Shares Are Trading Lower By More Than 48%; Here Are 37 Stocks Moving Premarket ↗

December 13, 2022

Gainers Netcapital Inc. (NASDAQ: NCPL) shares rose 91.3% to $2.65 in pre-market trading following Q2 results. Netcapital posted Q2 earnings of $0.04 per share on sales of $1.78 million.

Via Benzinga

How to Find Stocks That Rise 10x ↗

October 10, 2022

Investors looking for 10X stocks should prioritize companies in high-growth areas that demonstrate high earnings quality.

Via InvestorPlace

Longeveron: Q2 Earnings Insights ↗

August 12, 2022

Longeveron (NASDAQ:LGVN) reported its Q2 earnings results on Friday, August 12, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Insider Buying 2022: 15 Stocks to Bet On Despite the Bear Market ↗

October 05, 2022

Following insider buying is a savvy way for retail investors to profit even when a bear market is raging on Wall Street. Here are 15 stocks.

Via InvestorPlace

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

September 29, 2022

Gainers

Via Benzinga

These Stocks Are On The Radar After Biogen-Eisai's Surprising Alzheimer's Trial Win ↗

September 28, 2022

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

September 28, 2022

Gainers Acumen Pharmaceuticals (NASDAQ:ABOS) shares increased by 80.8% to $8.5 during Wednesday's pre-market session. The company's market cap stands at $344.2 million.

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗

September 28, 2022

It's time for another dive into the biggest pre-market stock movers as we check out what's going on on Wednesday morning.

Via InvestorPlace

Why MindMed Is Trading Lower By Around 35%; Here Are 31 Stocks Moving Premarket ↗

September 28, 2022

Gainers Atlis Motor Vehicles Inc (NASDAQ: AMV) rose 211.7% to $256.00 in pre-market trading after jumping around 199% on Tuesday.

Via Benzinga

Longeveron's Return On Capital Employed Insights ↗

September 09, 2022

Longeveron (NASDAQ:LGVN) brought in sales totaling $466 thousand during Q2 according to data provided by Benzinga Pro. However, earnings decreased 60.23%, resulting in a loss of $5.62 million.

Via Benzinga

PFE, MRNA Stocks: What to Know as the FDA Approves New Booster Shots ↗

August 31, 2022

Pfizer (PFE) and Moderna (MRNA) stocks are in the news Wednesday as the FDA approves new booster shots for the Covid-19 Omicron variant.

Via InvestorPlace

Why Is Longeveron (LGVN) Stock on the Move Today? ↗

August 31, 2022

Longeveron (LGVN) stock is on the move Wednesday after the FDA granted its fast-track designation for heart treatment Lomecel-B.

Via InvestorPlace

Longeveron Shares Ascend As FDA Grants Fast Track Status To Congenital Heart Disease Candidate ↗

August 31, 2022

Longeveron (NASDAQ: LGVN) received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for its lead drug Lomecel-B for the treatment of Hypoplastic Left Heart Syndrome (HLHS).

Via Benzinga

EXCLUSIVE: Longeveron's Lomecel-B Product Gets US FDA Fast Track Designation For Treatment Of Hypoplastic Left Heart Syndrome in Infants ↗

August 31, 2022

The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to Longeveron Inc (NASDAQ: LGVN) Lomecel-B for the treatment of Hypoplastic Left Heart...

Via Benzinga

European Patent Office Issues Intent To Grant Longeveron Patent Related To Methods To Monitor Efficacy Of Lomecel-B™ Cell Therapy ↗

August 26, 2022

Longeveron Inc. (NASDAQ: LGVN) announced that the European Patent Office (EPO) had issued a notice of its intent to grant the Company a patent (EP Application No.

Via Benzinga

EXCLUSIVE: Longeveron's Heart Disease Cell Therapy Poised To Secure European Patent ↗

August 25, 2022

The European Patent Office has issued a notice of its intent to grant Longeveron Inc (NASDAQ: LGVN) a patent related to methods to treat endothelial dysfunction and monitor the efficacy of allogeneic...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

August 24, 2022

Via Benzinga

Earnings Scheduled For August 12, 2022 ↗

August 12, 2022

Companies Reporting Before The Bell • NeoGenomics (NASDAQ:NEO) is projected to report quarterly earnings at $0.44 per share on revenue of $218.26 million.

Via Benzinga

Longeveron Earnings Preview ↗

August 11, 2022

Longeveron (NASDAQ:LGVN) is set to give its latest quarterly earnings report on Friday, 2022-08-12. Here's what investors need to know before the announcement. Analysts estimate that Longeveron will...

Via Benzinga

Is This Company In A Special Position Even As The COVID-19 Pandemic Affects Cell-Based Therapy Industry? ↗

August 09, 2022

According to Grand View Research, the global cell therapy market was valued at $7.8 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 14.5% between 2021 and 2028.

Via Benzinga

Publication Of Peer-Reviewed Study In Journal Of The Alzheimer's Association Could Mark A Significant Step For Longeveron ↗

August 02, 2022

Recent publishing of Longeveron Inc.’s (NASDAQ: LGVN)

Via Benzinga

Aging Veterans May Have New Options As VA And Longeveron Make Progress On Clinical Research Of Aging Frailty Treatment ↗

July 28, 2022

The U.S. Department of Veterans Affairs (VA) partnered with Longeveron Inc. (NASDAQ: LGVN) to explore the clinical-stage biotech’s novel cell therapies as a potential treatment for aging frailty.

Via Benzinga

7 Moonshot Investments Upending a $10 Trillion Industry ↗

July 08, 2022

Gene editing is expensive at an estimated $5 billion per drug, but it could change the world in the very near future.

Via InvestorPlace

This Low-Float Stock Jumps Around 148%; Here's 64 Biggest Movers From Yesterday ↗

July 08, 2022

Gainers United Maritime Corporation (NASDAQ: USEA) climbed 147.6% to close at $7.08 on Thursday on heavy momentum following the company's recent listing on the Nasdaq Capital Market.

Via Benzinga

Why U.S. Stocks Are Trading Higher After Rise In Jobless Claims ↗

July 07, 2022

U.S. stocks traded higher this morning, following the release of data on initial jobless claims.

Via Benzinga

This EV Maker Stock Jumps More Than 9%, Here's 46 Stocks Moving In Thursday's Mid-Day Session ↗

July 07, 2022

Gainers United Maritime Corporation (NASDAQ: USEA) jumped 180.4% to $8.02. The company’s stock jumped 190% on Wednesday after completing its spin-off from Seanergy Maritime Holdings Corp.

Via Benzinga

7 Ways to Prepare for a Recession: An Investor’s Guide ↗

June 24, 2022

There are plenty of ways to prepare for a recession. Here are seven ways you can make sure you're ready for whatever comes next.

Via InvestorPlace

Should Aging Be Treated As A Disease? And How One Company Might Be Shifting The Paradigm To Reverse It ↗

June 15, 2022

Technical advancements in stem cell therapies have reportedly shifted the outlook of regenerative medicine, and some scientists are getting increasingly excited.

Via Benzinga

How to Buy Stocks in a Recession ↗

May 16, 2022

The same strategies for buying stocks during a bull market don't apply during a recession. Learn what you need to do going forward.

Via InvestorPlace

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

16 17 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.